Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Gastroenterology > Reassuring data on immune checkpoint inhibitors in autoimmune disease

Reassuring data on immune checkpoint inhibitors in autoimmune disease

Journal
Annals of Internal Medicine
Doi
https://doi.org/10.55788/6405f342
    Reuters Health - 17/02/2021 - Patients with preexisting autoimmune disease (AIDs) are not at increased risk for immune-related adverse events from immune checkpoint inhibitor (ICI) therapy, although these adverse events may be more likely in patients with inflammatory bowel disease (IBD), new research indicates.

    "Therefore, we encourage physicians not to withhold ICI in most common AIDs. However, close monitoring in patients with IBD is advised because the incidence of severe colitis and early discontinuation of treatment due to toxicity was higher in this group," Dr. Ellen Kapiteijn with Leiden University Medical Center, the Netherlands, and colleagues advise in Annals of Internal Medicine.

    Because ICIs can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting AIDs were excluded from clinical trials, they explain.

    The researchers evaluated the safety and efficacy of ICI therapy in patients with advanced melanoma with and without AID, using the Dutch Melanoma Treatment Registry.

    A total of 415 patients (9.5%) had an AID, which was categorized as rheumatologic AID in 227, endocrine AID in 143, IBD in 55 and "other" in eight. Altogether, 228 of these patients (55%) received ICI therapy versus 2,546 (58%) patients who did not have an AID.

    Objective response rates were similar in patients with versus without AID who received anti-CTLA-4 therapy (10% vs 16%), anti-PD-1 therapy (40% vs. 44%), or the combination (39% vs. 43%). Survival rates were also similar in patients with and without AID (median, 13 months vs. 14 months).

    According to the researchers, there was no difference in the incidence of irAEs of grade 3 or higher in patients with and without preexisting AID of rheumatologic or endocrine origin.

    The incidences of grade 3 or higher irAEs in patients with AID were 30% with anti-CTLA-4 therapy, 17% with anti-PD-1 therapy and 44% with combination therapy; for patients no AID, the incidences were 30%, 13% and 48%, respectively.

    Patients with AID more often discontinued anti-PD-1 therapy due to toxicity than patients without AID (17% vs 9%). Patients with IBD were more prone to anti-PD-1-induced colitis (19%) than patients with other AIDs (3%) and patients without AID (2%).

    The researchers say their findings suggest no need to withhold ICI therapy in patients with common AIDs, although close monitoring in cases of IBD is warranted.

    Funding for the study was provided by the Netherlands Organization for Health Research and Development.

    SOURCE: https://bit.ly/3ba8vTF Annals of Internal Medicine, online February 15, 2021.

    By Reuters Staff



    Posted on